Pivotal BioSciences is focused initially on the development of three drugs, with other potential products in research:

PB101: a low toxicity analog of interleukin-2, an important cytokine already used in cancer immunotherapy. Pivotal's drug is modified to significantly improve the clinical utility of the approved version by decreasing toxicity without reducing efficacy. PB101 has been shown in animal studies to solve the problem of vascular leak syndrome toxicity associated with Proleukin®. Pivotal's improved version is expected to allow larger, more therapeutic dosages to be delivered to patients without the life-threatening side effects present in this FDA-approved therapy for renal cancer and melanoma, and which is being increasingly used "off-label" for HIV/AIDS patients with compromised immune systems and in conjunction with checkpoint inhibitor therapies.

PB103:This LEC/NHS76 fusion protein is a novel, potent immunotherapy agent based on Pivotal's platform LEC/mAb technology. The technology creates a fusion protein composed of a cancer-targeting antibody and the CC chemokine LEC (liver-expression chemokine, CCL16), which is a very potent chemoattractant to neutrophils, T-cells, macrophages, B-cells, and dendritic cells. Once at the tumor site, PB103 attracts and amplifies responding lymphoid and dendritic cells capable of inducing an effective anti-tumor immune response to the tumor. In animal studies, PB103 with one targeting moiety has shown efficacy when used alone, and has produced durable remissions of established colorectal and renal cancer when used in combination with another drug that inhibits immune suppression. In addition, a Phase I clinical trial in dogs with native canine tumors demonstrated proof of concept. Experiments with various targeting antibodies are now being developed, and Pivotal expects to license in or enter into joint ventures to obtain one or more promising targeting antibodies to further develop this compound. PB103 was selected by the National Cancer Institute for development in their RAID (Rapid Access to Interventional Development) program where process development was completed by SAIC.

PB105:This is LEC/rituximab, a "bio-better" version of Rituxan® shown in animal studies to be significantly more effective than Rituxan®

[ HOME ]

[ IN THE NEWS ]

[ MANAGEMENT TEAM ]

Pivotal BioSciences, Inc.
8721 Santa Monica Blvd.
Suite 100
Los Angeles, CA 90069

Tel: (310) 734-4551

Email: info@pivotalbiosciences.com



Pivotal BioSciences, Inc. © 2015. All Rights Reserved.